| Oct 24 |
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
|
| Oct 23 |
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
| Oct 9 |
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
| Sep 25 |
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
|
| Sep 4 |
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 3 |
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
|
| Aug 18 |
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 15 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 14 |
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
|
